Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › cyclophosphamide

cyclophosphamide

41 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of cyclophosphamide

596 trials tracked of cyclophosphamide: 108 in phase 3 or 4 and 61 with published results. The most-cited published study has 2776 citations.

596Trials tracked
108Phase 3 & 4
0Recruiting
61With published results
Phase distribution
Phase 4 5 Phase 3 103 Phase 2 430 Phase 1 38 Other / NA 20
  1. Phase 3 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed · 2,776 cited
  2. Phase 3 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer Completed · 1,104 cited
  3. Phase 3 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Completed · 1,018 cited
  4. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 742 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Completed · 702 cited
  6. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed · 608 cited
Show 44 more trials
  1. Phase 3 TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Completed · 607 cited
  2. Phase 3 Scleroderma: Cyclophosphamide or Transplantation Completed · 603 cited
  3. Phase 3 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed · 551 cited
  4. Phase 3 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Completed · 434 cited
  5. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 408 cited
  6. Phase 3 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed · 358 cited
  7. Phase 3 A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer Completed · 352 cited
  8. Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed · 343 cited
  9. Phase 3 Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma Completed · 276 cited
  10. Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 245 cited
  11. Phase 3 05-001: Treatment of Acute Lymphoblastic Leukemia in Children Completed · 241 cited
  12. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 230 cited
  13. Phase 3 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Completed · 230 cited
  14. Phase 3 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed · 216 cited
  15. Phase 3 Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment Completed · 209 cited
  16. Phase 3 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed · 207 cited
  17. Phase 3 Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) Completed · 184 cited
  18. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed · 181 cited
  19. Phase 3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Completed · 177 cited
  20. Phase 3 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed · 151 cited
  21. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 145 cited
  22. Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed · 140 cited
  23. Phase 3 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed · 125 cited
  24. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 125 cited
  25. Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Completed · 122 cited
  26. Phase 3 TBI Dose De-escalation for Fanconi Anemia Completed · 111 cited
  27. Phase 3 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Completed · 109 cited
  28. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 101 cited
  29. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 85 cited
  30. Phase 3 To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan Completed · 77 cited
  31. Phase 3 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Completed · 75 cited
  32. Phase 3 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Completed · 65 cited
  33. Phase 3 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Completed · 64 cited
  34. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 59 cited
  35. Phase 3 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients Completed · 58 cited
  36. Phase 3 Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Completed · 56 cited
  37. Phase 3 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Completed · 53 cited
  38. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 49 cited
  39. Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed · 48 cited
  40. Phase 3 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Completed · 39 cited
  41. Phase 3 A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia Completed · 35 cited
  42. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 34 cited
  43. Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 33 cited
  44. Phase 3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed · 32 cited

Showing the 50 most-cited and recently-updated of 596 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
Oncology Meta-analysis
Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles New analysis suggests specific chemo schedules may improve outcomes for early breast cancer patients
This network meta-analysis evaluated Phase II and Phase III trials involving 17,187 women with early-stage breast cancer receiving adjuvant…
A new analysis of 17,187 women with early breast cancer suggests specific chemo schedules may improve outcomes and reduce side effects.
Apr 9, 2026
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Hematology Phase II
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
CT.gov Apr 9, 2026
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Hematology RCT
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …
Apr 2, 2026
Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML
Hematology Phase II
Phase I/II trial tests IMRT with chemotherapy before transplant for relapsed/refractory ALL/AML Can a new radiation technique make stem cell transplants safer for leukemia?
A phase I/II trial record describes a study of intensity-modulated radiation therapy with etoposide and cyclophosphamide followed by allogen…
Doctors are testing a precise radiation technique to protect healthy organs while preparing patients for life-saving stem cell transplants.
CT.gov Mar 30, 2026
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
OB/GYN & Women's Health Phase II
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…
CT.gov Mar 30, 2026